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Objectives: Chronic cerebrospinal venous insufﬁciency (CCSVI) is associated with multiple sclerosis (MS).
The objective of the study was to see if percutaneous transluminal angioplasty (PTA) of duplex-detected
lesions, of the internal jugular and/or azygous veins, was safe, burdened by a signiﬁcant restenosis rate,
and whether there was any evidence that treatment reduced MS disease activity.
Design: This was a case-control study.
Materials: We studied 15 patients with relapsingeremitting MS and duplex-detected CCSVI.
Methods: Eight patients had PTA in addition to medical therapy (immediate treatment group (ITG)),
whereas seven had treatment with PTA after 6 months of medical therapy alone (delayed treatment
group (DTG)).
Results: No adverse events occurred. At 1 year, there was a restenosis rate of 27%. Overall, PTA was fol-
lowed by a signiﬁcant improvement in functional score compared with baseline (p < 0.02). The
annualised relapse rate was 0.12% in the ITG compared with 0.66% in the DTG (p ¼ NS). Magnetic
resonance imaging (MRI) blindly demonstrates a trend for fewer T2 lesions in the ITG (p ¼ 0.081),
corresponding to a 10% decrease in the ITG compared with a 23% increase in the DTG over the ﬁrst 6
months of the study.
Conclusions: This study further conﬁrms the safety of PTA treatment in patients with CCSVI associated
with MS. The results, despite the signiﬁcant rate of restenosis, are encouraging and warrant a larger
multicentre double-blinded, randomised study.
 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Chronic cerebrospinal venous insufﬁciency (CCSVI) is
a syndrome characterised by stenosis of the internal jugular and/or
azygous veins and formation of collateral venous channels. The
stenoses are mainly intraluminal defects, including vestigial
membranes, valve malformations and septae.1e3 Lesions that cause
CCSVI have been classiﬁed as truncal venous malformations and
they are morphological similar to abnormalities known to occur
within the iliac veins and inferior vena cava.4e6
Extracranial venous obstruction leads to inadequate cerebral
drainage. There appears to be a relationship between the severity of
extracranial haemodynamic abnormalities and perfusionwithin the
brain parenchyma.7 The latter can be studied with magnetic reso-
nance imaging (MRI) to assess cerebral blood ﬂow, cerebral blood
volume and the mean transit time from the arterial to the venous
side of cerebral circulation. In patients with multiple sclerosis (MS),: þ39 0532237443.
Elsevier Ltd on behalf of Europeanthere is evidence that the cerebral blood ﬂow is reduced and the
mean transit time increased, suggesting signiﬁcant abnormalities at
the microcirculatory level.8 There is an association between MRI-
detected cerebral ﬂow abnormalities and the Doppler venous
hemodynamic insufﬁciency severity score (VHISS) (Table 1),7 which
has been used to assess the haemodynamic severity of CCSVI.9,10 The
presence of this relationship demonstrates a possible link between
extracranial venous outﬂow obstruction, cerebral microcirculatory
changes and the course of patients’ MS.710
Duplex scanning uses a combination of physiological measure-
ments as well as anatomical imaging, and is the proper tool for
screening, permitting ﬂow evaluation in different postural and
respiratory conditions.13 Duplex has been tried by different centres
with variable results.1,1115 A high prevalence, ranging from 62% to
100%of obstructive lesions, has been foundby some teams inpatients
with MS compared with low prevalence (0e22%) in controls.1,1113
However, absence of such lesions or a lower prevalence has been
reported by others.14,15 This variability could be the result of differ-
ences in technique, training, learning curve or criteria used.16Society for Vascular Surgery.
Figure 1. Flow diagram of the EVT-MS study.
Table 1
Abbreviations used in the article.
9HPT 9-hole peg test
AT Acquisition time
AZ Azygous vein
CAL Combined active lesions
CCSVI Chronic cerebrospinal venous insufﬁciency
C.O.N.S.O.R.T. Consolidated Standards of Reporting Trials
CVIMS Chronic venous insufﬁciency in MS
DEVT Delayed endovascular treatment group
(operated 6 months from baseline)
DMT Disease-modifying therapy
DS Doppler sonography
DTPA Diethylene triamine pentaacetic acid
ECD EchoColor-Doppler
ETL Echo train length
EDSS Expanded disability status scale
EVT Endovascular treatment
EVT-MS Endovascular treatment study for MS
FA Flip angle
FLAIR Fluid attenuated inversion recovery
FOV Field of view
FSE Fast spin echo
FSPGR Fast spoiled gradient echo
Gd Gadolinium
HC Healthy controls
HDNV Multi-channel head and neck coil
HIRES 3D high-resolution
IEVT Immediate endovascular treatment group
of patients (operated at baseline)
IJV Internal Jugular Vein
IR Inversion recovery
IRB Institutional review board
LV Lesion volume at MRI, assessed both in T1 and T2
LVV Lateral ventricle volume
MS Multiple sclerosis
MRI Magnetic resonance imaging
MSFC Multiple sclerosis functional composite
NABT Normal-appearing brain tissue
PASAT Paced auditory serial addition test
PBVC Percent brain volume change
PD Proton density
PTA Percutaneous transluminal angioplasty
RR Relapsingeremitting
SE Spin echo
SIENA Structural image evaluation using normalization of atrophy
SIENAX Structural image evaluation using normalization
of atrophy, cross-sectional
SPSS Statistical package for the social sciences
T25FW Timed 25-ft walk
TE Echo time
TI Inversion time
TR Repetition time
VH Venous haemodynamic
VHISS Venous haemodynamic insufﬁciency severity score
WI Weighted image
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(PTA) of CCSVIwas reported to be feasible as a day surgery treatment,
with a minimal complication rate.2 Postoperative venous pressures
were signiﬁcantly reduced. Thismethodwas criticised because of the
lack of a control group and blinded, objectiveMRImeasurement. The
study was also criticised for using a potentially dangerous treatment
without evidence of neurological and vascular safety.17
The present study was designed to address these criticisms and
to determinewhether treatment of CCSVI with PTA affected disease
progression in patients with MS.
Methods
Participants
Sixteen patients with MS, who had been the subjects in the
chronic venous insufﬁciency in MS study (CVIMS),7,9,10,18 wereasked to participate. The CVIMS was a pilot collaborative study
between the University of Buffalo and the Universities of Ferrara
and Bologna, Italy that involved patients with relapsingeremitting
MS19 and age- and sex-matched healthy controls. All the patients
with MS fulﬁlled the duplex ultrasound CCSVI venous haemody-
namic (VH) criteria. The duplex prevalence of CCSVI in MS was
100%, whereas, in eight normal subjects used as controls in the
CVIMS studies, the prevalence was 0%.7,9 Of the 16 patients, 15 met
the inclusion/exclusion criteria and agreed to participate (eight
from Italy and seven from Buffalo).
Inclusion criteria were: patients with a diagnosis of MS
according to the McDonald criteria,19 who were on treatment with
Food and Drug Administration (FDA) e approved disease e modi-
fying treatments and who were aged between 18 and 65 years.
Their expanded disability status scale (EDSS) had to range from 0 to
5.5, they had to have more than two areas of abnormal extracranial
cerebral venous outﬂow that met VH criteria1,2 and had to have
normal kidney functioning (creatinine clearance >59 ml/min).
Exclusion criteria were: pregnancy, relapse of MS, disease
progressionandsteroid treatmentwithin the30daysprecedingstudy
entry, pre-existing medical conditions known to be associated with
brain pathology (e.g., neurodegenerative disorder, cerebrovascular
disease, positive history of alcohol abuse and so on) and contraindi-
cation for receiving gadolinium (Gd)-based contrast agents.
Design
The study was designed to have half of the cohort treated at
baseline (immediate treatment group (immediate), four fromBuffalo
and four from Italy) and half of the cohort delayed for 6 months
(delayed treatment group (delayed)). Patients were selected
randomly to undergo PTA immediately after baseline screening. For
the Buffalo MS patients, group selection was simply based on the
availability of an international travel document (only four patients
had passports available at baseline, whereas the three patients
assigned to the delayed group needed to wait to obtain one). The
Italian patients were randomly assigned to their groups by alpha-
betical order. Fig. 1 illustrates the study design, in accordance to
CONSORT (Consolidated Standards of Reporting Trials) requirements.
All interventions took place in Ferrara, Italy. Catheter venog-
raphy of the major extracranial and extravertebral segments of the
cerebrospinal veins was done according to a protocol previously
described.2 Patientswere then given 5000 IU of intravenous heparin
and the lesions identiﬁed were treated with PTA. Lesions of the
azygous vein were treated with 8e10-mm-diameter angioplasty
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pressure of 8 atm. Inﬂations were held for 30e60 s and repeated
several times, as required.
PTA of stenosed internal jugular veins was performed ﬁrst with
a compliant balloon (10e12 mm diameter, 2e4 cm length), which
was then inﬂated to 8 atm. Smaller-calibre balloons were selected
in cases of severe atresia or segmental hypoplasia. The compliant
balloons were used not only for therapeutic dilation but also as
ameans of assessing the resistance of the stenosis and the degree of
wasting of the balloon during maximum dilation. In the event of
a poor post-procedural outcome, the treatment was repeated with
a non-ﬂexible high-pressure balloon (18e20 atm) of equal diam-
eter and length to the compliant balloon.
End points
The primary end points of the study were safety, patency rate
and the effect of PTA on brain lesions, as well as relapse rate. These
were investigated by monitoring adverse events related to PTA at 1,
6 and 12 months. The effect of treatment was measured by the
annualised relapse rate and the proportion of patients who were
relapse-free in each group. Brain lesions were assessed by counting
the number of new active lesions on T2- and T1-weighted post-
contrast MRI serial scans and changes in lesion volumes (LVs).
MRI assessment was done at baseline, 6 and 12 months.
The secondary end points of the study were to investigate the
efﬁcacy of immediate vs. delayed PTA on clinical outcomes (relapse
rate, EDSS, multiple sclerosis functional composite (MSFC)) and
changes in whole brain volume (percent brain volume change
(PBVC)).
Clinical outcome measures
All patients underwent neurological examinations, EDSS scoring
and MSFC evaluations followed by duplex ultrasound at baseline, 3,
6, 9 and 12 months. In addition, the rate of annualised relapse rate
and the percentage of patients relapse-free were assessed. EDSS
was done by neurologists specialising inMS, whereas theMSFCwas
performed by a credentialled researcher.
Neurological outcomemeasures usually adopted in clinical trials
in MS were used including, the authors’ ﬁrst open-label evaluation
of PTA.2 The Kurtzke EDSS is a method of quantifying disability in
MS. The EDSS categorises a person’s level of disability.20 EDSS
scores range from 0 to 10, with higher scores indicating more
severe disability. It is an important tool in clinical practice because
it is widely used and takes a snapshot of the clinical situation.
The MSFC is a multidimensional clinical outcome measure
consisting of quantitative timed tests of leg function/walking
(Timed 25-Foot Walk, T25FW), group function (Nine-Hole Peg Test,
9HPT) and cognitive function (paced auditory serial addition test,
PASAT) expressed as a single score along a continuous scale.21,22
The composite score was calculated by adding the z-scores ob-
tained and dividing the sum by 3, as described in the following
formula: MSFC Score ¼ (z-arm, average  z-leg, average þ z-
cognitive, average)/3.0. Z-score is a method of standardisation,
a process that leads a random variable distributed according to an
average m and variance s2, a random variable with distribution of
‘standard’, that is, 0 mean and variance of 1.
MRI assessments and analysis
Image acquisition
MR assessments were done at the University of Buffalo, USA. All
subjects were examined in a 3T GE Signa Excite HD 12.0 Twin Speed
8-channel scanner (General Electric, Milwaukee, WI, USA), witha maximum slew rate of 150 T m1 s1 and maximum gradient
amplitude in each orthogonal plane of 50 mT m1 (zoom mode). A
multi-channel head and neck (HDNV) coil manufactured by GE was
used to acquire the following sequences: two-dimensional (2D)
multiplanar dual fast spin echo (FSE) proton density (PD) and T2-
weighted image (WI); ﬂuid-attenuated inversion recovery (FLAIR);
and three-dimensional (3D) high-resolution (HIRES) T1-WI using
a fast spoiled gradient echo (FSPGR) with magnetisation-prepared
inversion recovery (IR) pulse and spin echo (SE) T1-WI with and
without using a single-dose intravenous bolus of 0.1mMol kg1 Gd-
diethylene triamine pentaacetic acid (Gd-DTPA) 5 min after injec-
tion. All scans were prescribed in an axialeoblique orientation,
parallel to the subcallosal line.
Lesion measures
The lesion-activity analysis was performed between baseline and
6 months and 6 and 12 months by identifying the number of new
active lesions and active scans. A new Gd-enhancing lesion was
deﬁned as a typical area of hyperintense signal on post-contrast T1-
weighted image. Other Gd-based MRI lesion-activity outcomes
included the number of total Gd-enhancing lesions per patient and
the number of persistent Gd-enhancing lesions (enhancing lesions
were also present on the previous scan). A new or newly enlarging
lesion onT2-weighted imageswasdeﬁned as a roundedoroval lesion
arising from an area previously considered normal-appearing brain
tissue (NABT) and/or showing an identiﬁable increase in size from
a previously stable-appearing lesion. Other T2-based MRI lesion-
activity outcomes included the number of newly enlarging, persis-
tently enlarging or recurrent T2 lesions. The authors also determined
the number of combined active lesions (CALs), deﬁned as new
enhancing lesions plus the number of new or newly enlarging, non-
enhancing lesions on T2-weighted image. The T2- and T1-LVs (T1-LV
andT2-LV) were measured using a semi-automated edge-detection
contouring/thresholding technique previously described.
Global and central brain volume measures
For brain extraction and normalized brain volume (NBV) esti-
mation, the structural image evaluation, using normalization, of
atrophy cross-sectional (SIENAX) software tool was used, with in-
house-developed corrections for T1-hypointensity lesion misclas-
siﬁcation. PBVC was measured using the structural image evalua-
tion, using normalization, of atrophy (SIENA) method. The baseline
scan was co-registered with the follow-up scan at any time point,
and an analysis of relative edge motions was used to calculate the
PBVC between all available time intervals. The lateral ventricle
volume (LVV) was calculated using a semi-automated approach.Statistical analysis
Statistical analysiswas performed using the Statistical Package for
the Social Sciences (SPSS, Version 16.0) by an independent statisti-
cian. For comparisons between the groups, the two-tailed Fisher
exact test, the Student’s t-test, the ManneWhitney U test and the
Wilcoxon rank sum test were used, as appropriate. The minimum
signiﬁcance was 0.05. All p values were based on two-tailed tests.Results
Baseline characteristics
There were no signiﬁcant baseline demographic differences
between MS patients (Table 2). All patients were on disease-
modifying therapy (DMT, Table 2) unchanged for at least 6
months before enrolment. Table 2 also displays the venous duplex
Table 2
Baseline characteristics in multiple sclerosis patients (total and according to the treatment group).
Multiple sclerosis
(n ¼ 15)
Immediate Treatment
Arm (n ¼ 8)
Delayed Treatment
Arm (n ¼ 7)
Female gender, N (%) 10 (66.7%) 4 (50.0%) 6 (85.7%)
Age y.o., median (range) 36 (23e49) 36 (23e49) 36 (31e38)
Age at Onset y.o., median (range) 28 (15e44) 29.5 (15e44) 27 (23e30)
Disease Duration y., median (range) 8 (5e10) 7 (5e9) 8 (5e10)
Number of Relapses in the year prior to baseline, median (range) 0 (0e2) 0 (0e2) 0 (0e1)
Number of Relapses in the year prior to baseline, N (%)
0 12 (80.0) 7 (87.5) 5 (71.4)
1 2 (13.3) e 2 (28.6)
2 1 (6.7) 1 (12.5) e
EDSS, median (range) 2.5 (1.5e5.5) 2.0 (1.5e5.5) 3.0 (1.0e3.5)
MS Functional Composite Components (mean, SD)
PASAT (Number Correct) 45.5 (9.5) 46.3 (12.6) 44.6 (5.2)
25 foot timed walk (sec) 4.9 (1.1) 5.0 (1.3) 4.7 (0.9)
9 hole peg test dominant hand (sec) 23.5 (7.2) 22.8 (2.8) 24.4 (10.5)
Disease-modifying therapy in the year prior to baseline, N (%)
Interferon-beta 1a 10 (66.7%) 5 (62.5%) 5 (71.4%)
Glatiramer acetate 2 (13.3%) 1 (12.5%) 1 (14.3%)
Natalizumab 3 (20.0%) 2 (75.0%) 1 (14.3%)
Number of VH Criteria fulﬁlled, median (range) 4 (2e5) 4 (2e5) 4 (3-5)
VH Criteria Met, N (%)
1 11 (73.3) 6 (75.0) 5 (71.4)
2 14 (93.3) 7 (87.5) 7 (100.0)
3 13 (86.7) 7 (87.5) 6 (85.7)
4 13 (86.7) 7 (87.5) 6 (85.7)
5 7 (46.7) 4 (50.0) 3 (42.9)
Total number of GAD enhancing lesions, median (range) 0 (0e5) 0 (1-5) 0.0 (0.0)
Total volume of GAD enhancing lesions, cm3, median (range) 0 (0e0.16) 0 (0e0.16) 0.0 (0.0)
T2 Lesion Volume, cm3, median (range) 4.9 (1.5e37.8) 4.1 (1.5e37.8) 4.9 (3.2e9.9)
T1 Hypointense Lesion Volume, cm3, median (range) 1.2 (0.08e11.9) 1.2 (0.08e11.9) 1.2 (0.4e5.7)
Normalized BV, cm3, median (range) 1528.6 (1280e1612.8) 1588.1 (1490.4e1621.4) 1478.6 (1280e1612.8)
Lateral Ventricle Volume, cm3, median (range) 15.6 (3e39.7) 14.6 (3e32.1) 20.6 (6.7e39.7)
Legend: N e number; EDSS e Expanded Disability Status Scale; VH e venous haemodynamic; GADe gadolinium; BVe brain volume. All volumes are expressed in centimeter
cubes (cm3).
The data for delayed treatment group are shown at baseline. Delayed treatment arm started the endovascular treatment after 6 months of follow-up and the patients were
followed for another 6 months.
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patients.
Safety and tolerability
Venography conﬁrmed duplex diagnosis of CCSVI in 100% of
cases. No adverse events or major complications were reported,
including bleeding, allergy and problems related to contrast media.
Patients were discharged the same day. One case of vasovagal
syncope was reported 3 h after the procedure. One dropout
occurred in the delayed group at the 3 months’ follow-up for
familial reason.
Restenosis
Overall, restenosis occurred at 1 year in 27% of cases. Restenosis
was detected bymeans of duplex ultrasound in four patients, in two
in the delayed group at 9 months follow-up and one in the delayed
and one in the immediate group at 12-month follow-up. Restenoses
were conﬁned to the jugular veins.
Clinical outcome measures
There were ﬁve relapses during the study, one in the immediate
group and four in the delayed group. The annualised relapse rate
was 0.12% in the immediate group compared with 0.66% in the
delayed group. Seven out of eight patients (88%) were relapse-free
at 1 year in the immediate group compared with three of six (50%)
in the delayed group (p ¼ NS). The one relapse in the immediategroup occurred in a patient who presented at 12 months with 16
new CALs. In the delayed group, one patient had two relapses and
two patients had one relapse.
There were no signiﬁcant changes in EDSS over 12 months
between the two treatment groups. There was signiﬁcant
improvement in MSFC compared with baseline over 0e6 months
(p < 0.02) and 0e12 months (p < 0.02) in both immediate and
delayed groups.MRI outcome measures
Details of primary and secondary MRI end points are given in
Table 3, as well as T2-, T1- and Gd-LV changes over the follow-up
period. There was a trend for lower accumulation of T2-LV in the
immediate group over 0e6 months (5.8% vs. þ23%, p ¼ 0.081).
Further, the decrease of T1-LV was higher in the immediate group
compared with the delayed group over 12 months (36.8%
vs. 13.5%, p ¼ NS).
At 6 months, brain volume was reduced by 1.35% in the imme-
diate group, compared with 0.8% in the delayed group. At 12
months, the ﬁgures were 0.82% volume reduction in the immediate
group and 0.82% in the delayed group. No differences in lateral
ventricular volumewere seen between the groups after 12 months.
The mean number of new CALs was 4.5 in the immediate and
two in the delayed group. The increased number of new active
lesions in the immediate group was mainly because of the
increased activity detected in just one MS patient, who presented
with 16 new CALs and the relapse.
Table 3
Primary and secondary MRI endpoints in multiple sclerosis patients (according to treatment group).
IEVT Group at 6
months (N ¼ 8)
DEVT Group at 6
months (N ¼ 6)
IEVT Group at 12
months (N ¼ 8)
DEVT Group at
12 months (N ¼ 6)
Total number of new CAL,
median (range) sum
0.5 (0e3) 12 1.5 (03) 5 3 (0-16) 36 1.5 (0-6) 12
Active CAL scans in individual patients, N (%) 6 (75) 3 (50) 5 (62.5) 4 (66.7)
Total number of new Gd lesions,
median (range) sum
0 0 0 (0e9) 9 0 (0-1) 1
Active Gd scans in individual patients, N (%) 0 0 1 (12.5) 1 (16.7)
Total number of new T2 lesions,
median (range) sum
0.5 (0e3) 12 1.5 (03) 5 3.5 (0e13) 34 1.5 (0e5) 12
Active T2 scans in individual patients, N (%) 6 (75) 3 (50) 4 (50) 4 (66.7)
T2-LV % change, median (range) 8.9 (52.5 to þ15.6) þ19.4 (10.3toþ74) 3.8 (55.6toþ32.8) þ20.3 (26.3 to þ78.5)
T1-LV %, median (range) 37.6 (36.3 to þ52.7) 31.2 (72.4 to þ3.8) 36.8 (30.1) 15.2 (53.4 to þ28.4)
PBVC, median (range) 1.27 (6.6 to þ1.1) 0.57 (1.8 to 0.3) 0.69 (3.3 to þ0.9) 0.84 (1.1 to þ1.4)
LVV % change, median (range) þ1.2 (17 to þ7.2) þ5.6 (þ0.0 to þ14.2) þ9.2 (6.2 to 16.4) þ2.3 (9.7 to þ10.9)
Legend: CAL e combined active lesion; Gd e gadolinium; LV e lesion volume; PBVC e percent brain volume change; LVV e lateral ventricle volume.
PBVC was obtained using automated SIENA technique. LVs and active lesions were assessed by a semi-automated method. LVV was calculated by manual measurement.
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Safety of endovascular treatment of CCSVI has been evaluated in
a large observational study in 564 consecutive cases; major
complications including rupture, thrombosis and stent migration
were not reported at all, whereas minor complications were
observed in 2% of cases.23 Our study conﬁrms that PTA in expert
hands is safe and well tolerated.2 PTA is a conservative treatment
and does not expose patients to the risks of migration or other
complications related to the use of stents.2,4,17
In the present study, measurement of MRI lesion activity was
especially used for further safety purposes because, prior to this
study, little was known about the neurological consequences of
venous PTA in the brain. Lesion activity was increased in the
immediate group with respect to the delayed group; however, this
effect was mostly driven by high activity in one patient, who
accounted for 16 new CALs. The two hypotheses for explaining this
paradoxical effect are that (1) the patient did not respond to PTA or
(2) reopening of the veins increased perfusion of the micro-
circulation of the brain parenchyma, which resulted in short-term
inﬂammation. There may be other reasons. This speciﬁc patient
had a very active disease.
In the present study, the restenosis rate was lower than previ-
ously reported, being 27% compared with 47%.2 Interestingly,Figure 2. A) Catheter venography depicts a membranous obstruction at the level of the azy
valve apparatus. However, this is located at the outlet with the superior vena cava and is con
is rejected by a membranous obstruction. C) After perforation of the membrane the balloorestenosis was observed exclusively in the territory of the jugular
vein and not at all in the azygous vein. This ﬁnding conﬁrms that
PTA may be an appropriate treatment for the azygous vein, with
a high probability of success at the ﬁrst attempt (Fig. 2).2
PTA was followed by a signiﬁcant improvement in MSFC
(p < 0.02).2 MSFC was chosen as outcome measure because it is
considered a detailed test assessing the disability in MS; it inte-
grates motor function of the lower and upper extremities, coordi-
nation and cognitive function, and is highly recommended in MS
clinical trials.21,22
MSFC changes usually require longer than a 1-year follow-up
period to provide a signiﬁcant clinical change in large MS trials.
From this point of view, this ﬁnding is particularly interesting in our
study. The authors did not prevent the possible improving effect
related to the practice of theMFSC test by the patients because they
also used the additional control measure EDSS that does not
include this effect. The EDSS stability conﬁrms the signiﬁcant
improvement of MFSC.
In a previous study, there was also reported a signiﬁcant
reduction of the number of relapse-free patients following venous
angioplasty.2 By comparing the groups over 0e6 months, the
annualised relapse rate and the percentage of relapse-free patients
were, respectively, 0.12% and 88% in the immediate group and
0.66% and 50% in the delayed one. The decreased relapse rategous arch (arrow). It has been described in some cases as a possibility for a rudimental
ﬁned to the venous wall without signiﬁcant protrusion in the lumen. B) The guide wire
n is inﬂated. D) Postoperative control demonstrates the patency of the azygous vein.
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group, albeit not signiﬁcant, seems to indicate that PTA could
potentially enhance the effect of medication given to patients with
MS.
There was a trend for lower accumulation of T2 LV on MRI in the
immediate group (p ¼ 0.081), corresponding to a 10% decrease in
the immediate group compared with a 23% increase in the delayed
group over the ﬁrst 6 months. This difference was maintained over
the 12-month follow-up. The potential therapeutic role of PTA is
apparently conﬁrmed by the higher decrease in the T1-LV in the
immediate group compared with the delayed group over 0e6
months.
One problem with every potential anti-inﬂammatory therapy
used in patients withMS is that each of them decreases whole brain
volume more rapidly in the treated vs. the placebo group due to
reduced inﬂammation in the ﬁrst couple of months of treatment,
with any beneﬁcial effect only becoming evident afterwards. This
accelerated-treatment-related brain-volume reduction is known as
‘pseudoatrophy’.24 The higher percent brain-volume change
decrease over the ﬁrst 6 months (1.35%) in the immediate group
suggests a more pronounced pseudoatrophy effect compared with
the delayed group (0.8%), possibly because of a potential anti-
inﬂammatory effect of PTA. Alternatively, a decrease in brain
volume might be because of better venous drainage following
angioplasty.25,26 No differences were seen over 12 months between
the two treatments groups.
The aetiology and pathogenesis of MS remain largely unknown.
It is believed to be an immune-mediated disorder of multifactorial
origin.27,28 MS association with CCSVI have been found in duplex
ultrasound studies.1,1117 This cohort of patients was a part of the
CVIMS studies presenting a 100% prevalence of CCSVI in MS vs. 0%
in controls.7,9 In the present study, this prevalence was further
validated by venography.
In addition, CCSVI shares common genetic components with
MS,29 may cause signiﬁcant transstenotic gradient of venous pres-
sure2 and, ﬁnally, is associated with abnormal cerebrospinal ﬂuid
dynamics9,10 as well as with hypoperfusion of brain parenchyma.7
The above ﬁndings support a role of CCSVI in MS pathogenesis.
Moreover, from a clinical point of view, the reduction of chronic
fatigue after venous PTA in MS patients seems to indicate this as
a peculiar symptom of CCSVI in the complex MS picture.30 The
accepted possibility of a multifactorial pathogenesis has, of course,
therapeutic implications because more than one approach to
treatment may be required in curing this disease effectively.27 From
this point of view, PTA could be a further therapeutic contributor to
the management of MS.2
PTA of venous lesions cannot be recommended as a treatment
for MS based on the results of this study. However, our data conﬁrm
that treatment of CCSVI was related to changes in the clinical and
MRI outcome measures of patients with MS, and warrant a trial
with large number of patients and double-blind methodology to
minimise the placebo effect.
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